Follow-up and record-keeping of patients with chronic liver disease after vaccination was carried ou

Recently, global medical institutions and public health systems have continued to advance service capacity building to provide stronger guarantees for public health. Patients with chronic liver disease (CLD) often experience varying degrees of immune dysfunction, making them vulnerable to multiple preventable infectious diseases when vaccinated appropriately. In order to assess the vaccination status and vaccine coverage of CLD patients during treatment in tertiary care institutions, the study conducted a clinical survey of 200 patients receiving treatment for CLD from tertiary care institutions.

This cross-sectional observational study was conducted in the Liver External Clinic at St. Paul's City Hospital, a medical institution affiliated with the University of St. Paul, including the University of St.

Paul School of Medicine and the Liver External Clinic at St. Paul's City Hospital. In order to obtain large samples of CLD patients with different diseases, we randomized patients into adult CLD patients for cross-sectional observational studies, and then randomly assigned patients to different samples of cross-sectional observational studies, thus obtaining large samples of CLD patients with different diseases.

Participants received standardized interviews, a review of vaccine records and a skin test of anti-HAV and anti-HB antibodies. Among 104 patients, the most common cause of chronic hepatitis (CLD) was anti-HAV and anti-HB antibodies. Among 46.

1% of patients, advanced liver disease occurred. The vaccination record was available to 82. 7% of participants, but only 45.

1% of participants showed serological evidence of anti-HBs positive hepatitis B immunization. Serological evidence of anti-HBs IgG-positive immunization against hepatitis B was recorded in 75% of participants, compared with only 14. 4% of participants.

Other vaccine coverage rates were as follows: human breast tumour subtype vaccine (8. 7%); pneumococcal vaccine (PPSV2325%); flu vaccine (53. 8%); scurvy-threonate vaccine (60.

6%); measles-threonate vaccine (23%); Vaccine coverage for people with chronic liver disease remains lower than expected, especially in recommended vaccination centres, and this finding highlights the importance of systematic evaluation of the vaccination status of people with chronic liver disease and the strengthening of vaccination strategies in patients with chronic liver disease. It should be noted that the above information is based on international public research and is provided for reference by HealthCoop and does not constitute clinical advice. If you have any health questions, please consult professional medical professionals.